trending Market Intelligence /marketintelligence/en/news-insights/trending/w0ygckaqjlur7linqk5i6g2 content esgSubNav
In This List

ASCO conference: Sellas' ovarian cancer drug slows disease progression

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


ASCO conference: Sellas' ovarian cancer drug slows disease progression

Sellas Life Sciences Group Inc. said a combination of its lead product candidate galinpepimut-S and Bristol-Myers Squibb Co.'s Opdivo slowed disease progression by a year in patients with ovarian cancer.

The company was presenting interim data from a phase 1 study at the 2018 American Society of Clinical Oncology meeting in ovarian cancer patients expressing the Wilms tumor gene 1 who went into remission for the second or third time.

Based on the early data, 70% of the 10 patients who were treated with at least three doses of the combination were alive for a year without their disease worsening.

Additionally, 64% of 11 patients in an intent to treat group survived for a year without disease progression.

The company will conduct a phase 1/2 trial of the drug in combination with Merck & Co. Inc.'s Keytruda in different tumor types, including WT1 positive ovarian cancer in the third quarter.

The 2018 American Society of Clinical Oncology meeting is expected to bring together more than 32,000 professionals from all over the world, with more than 2,500 study abstracts to be presented on-site and an additional 3,350 abstracts to be published online.